Comparison of MRI-based thrombolysis for patients with middle cerebral artery occlusion 3 h and 3-6 h

Neurology India

Volumn 57, Issue 4, 2009, Pages 426-433

  Li, Yue Hua ^a,c   Li, Ming Hua ^a   Zhao, Zhen Guo ^b   Bai, Qing Ke ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b People's Hospital of Pudong New Area   (China)

^c NONE   (China)

Author keywords

Magnetic resonance imaging; Middle cerebral artery; Recombinant tissue plasminogen activator; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE;

ACUTE DISEASE; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RANKIN SCALE; RECANALIZATION; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; CEREBRAL ANGIOGRAPHY; DIFFUSION MAGNETIC RESONANCE IMAGING; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 70349433773     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.55615     Document Type: Article

References (25)

1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587
2. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience. JAMA 2000;283:1151-1158
3. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001;56:1015-1020
4. O'Connor RE, McGraw P, Edelsohn L. Thrombolytic therapy for acute ischemic stroke: Why the majority of patients remain ineligible for treatment. Ann Emerg Med 1999;33:9-14
5. Röther J, Schellinger PD, Gass A, Siebler M, Villringer A, Fiebach JB, et al. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke , 6 hours. Stroke 2002;33:2438-2445
6. Schellinger PD, Jansen O, Fiebach JB, Heiland S, Steiner T, Schwab S, et al. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI. Stroke 2000;31:1318-1328
7. Parsons MW, Barber PA, Chalk J, Darby DG, Rose S, Desmond PM, et al. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002;51:28-37
8. Köhrmann M, Jüttler E, Fiebach JB, Huttner HB, Siebert S, Schwark C, et al. MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: A cohort study. Lancet Neurol 2006;5:661-667
9. Molina CA, Montaner J, Abilleira S, Arenillas JF, Ribó M, Huertas R, et al. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: A case-control study. Stroke 2001;32:2821-2827
10. Sanák D, Nosál' V, Horák D, Bártková A, Zelenák K, Herzig R, et al. Impact of diffusion-weighted MRI-measured initial cerebral infarction volume on clinical outcome in acute stroke patients with middle cerebral artery occlusion treated by thrombolysis. Neuroradiology 2006;48:632-639
11. Straub S, Junghans U, Jovanovic V, Wittsack HJ, Seitz RJ, Siebler M. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Stroke 2004;35:705-709
12. Bai Q, Zhao Z, Li Y, Sui H, Xie X, Gong Y, Zhao X, Wang L, Xia W, Shen J, Lu L. The application of fast multiparametric protocol MRIbased thrombolysis with rt-PA hyperacute cerebral infarction. Neurol Res 2008;30:344-347
13. Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, et al. Improved reliability of the NIH stroke scale using video training. Stroke 1994;25:2220-2226
14. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607
15. Lövblad KO, Baird AE, Schlaug G, Benfield A, Siewert B, Voetsch B, et al. Ischemic lesion volumes in acute stroke by diffusion-weighted magnetic resonance imaging correlate with clinical outcome. Ann Neurol 1997;42:164-170 (Pubitemid 27340460)
16. Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, et al. Trial design and reporting standards for intraarterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003;34:e109-37
17. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: Phase I findings. N Engl J Med 1985;312:932-936
18. Haley EC, Lewandowski C, Tilley BC. Myths regarding NINDS rtPA Stroke Trial: Setting the record straight. Am Emerg Med 1997;30:676-682
19. Demchuk AM, Burgin WS, Christou I, Felberg RA, Barber PA, Hill MD, et al. Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke 2001;32:89-93
20. Christou I, Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff M, et al. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke. Stroke 2000;31:1812-1816
21. Alexandrov AV, Demchuk AM, Felberg RA, Christou I, Barber PA, Burgin WS, et al. High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2-MHz transcranial doppler monitoring. Stroke 2001;31:610-614
22. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-1251
23. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: A randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA 1999;282:2019-2026
24. Kent DM, Hinchey J, Price LL, Levine SR, Selker HP. In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous? Stroke 2004;35:1141-1146
25. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA stroke study group. Stroke 1997;28:2109-2118